Please ensure Javascript is enabled for purposes of website accessibility

Johnson & Johnson Aiming to Enroll One-Third of Phase 3 Trial Patients From Latin America

By Eric Volkman – Sep 5, 2020 at 1:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company hopes to recruit 20,000 people from the region for the late-stage study.

Johnson & Johnson (JNJ 0.13%) is looking south of the U.S. border for participants in a phase 3 clinical trial of its coronavirus vaccine candidate. The company said it aims to enroll 20,000 people from Latin America for the study, roughly one-third of the planned worldwide total.

Specifically, "[w]e expect the majority in Brazil because it's the biggest country and also the one most affected by the pandemic so we expect a lot of people volunteering, but we expect also high numbers in Colombia and in Argentina," said Josue Bacaltchuk, the vice president of medical affairs for Janssen Vaccines (the Johnson & Johnson subsidiary developing the candidate, Ad26.COV2-S), in an interview with Reuters.

A syringe being filled with a vaccine from a vial.

Image source: Getty Images.

Additionally, when and if Ad26.COV2-S is approved for use, countries hosting trials -- presumably including those South American ones -- will probably receive preferential access to it, Bacaltchuk said.

The region has been especially hard-hit by the coronavirus outbreak, with a relatively high number of both cases and fatalities. Many health experts have raised concern that the more badly affected parts of the world will be underserved once a vaccine is approved and ready for use. 

The news about Johnson & Johnson's enrollment comes on the heels of a similar development with the company many consider to be the leader in the COVID-19 vaccine "race," Moderna (MRNA -0.23%). Stephane Bancel, Moderna's CEO, said Friday that his company was slowing the enrollment in the phase 3 trial of its coronavirus vaccine candidate to ensure sufficient participation of minority groups.

Johnson & Johnson and Moderna are two of only a handful of companies that are entering phase 3 trials for vaccine candidates. No COVID-19 vaccine has yet been approved for widespread use by any major regulator.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$177.24 (0.13%) $0.23
Moderna Inc. Stock Quote
Moderna Inc.
MRNA
$176.40 (-0.23%) $0.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.